Suzhou Zelgen BiopharmaceuticalsLtd Future Growth
Future criteria checks 5/6
Suzhou Zelgen BiopharmaceuticalsLtd is forecast to grow earnings and revenue by 107.9% and 55.8% per annum respectively. EPS is expected to grow by 107.9% per annum. Return on equity is forecast to be 9.9% in 3 years.
Key information
107.9%
Earnings growth rate
107.9%
EPS growth rate
| Biotechs earnings growth | 33.1% |
| Revenue growth rate | 55.8% |
| Future return on equity | 9.9% |
| Analyst coverage | Low |
| Last updated | 08 May 2024 |
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,181 | 312 | -228 | 398 | 3 |
| 12/31/2025 | 1,349 | 129 | -364 | -55 | 3 |
| 12/31/2024 | 750 | -68 | -232 | -237 | 3 |
| 3/31/2024 | 387 | -261 | -186 | -113 | N/A |
| 12/31/2023 | 386 | -279 | -295 | -233 | N/A |
| 9/30/2023 | 387 | -296 | -377 | -319 | N/A |
| 6/30/2023 | 417 | -325 | -419 | -345 | N/A |
| 3/31/2023 | 367 | -395 | -423 | -341 | N/A |
| 12/31/2022 | 302 | -457 | -459 | -370 | N/A |
| 9/30/2022 | 290 | -522 | -499 | -407 | N/A |
| 6/30/2022 | 253 | -521 | -490 | -399 | N/A |
| 3/31/2022 | 234 | -491 | -494 | -411 | N/A |
| 12/31/2021 | 190 | -451 | -525 | -455 | N/A |
| 9/30/2021 | 98 | -384 | -518 | -449 | N/A |
| 6/30/2021 | 70 | -368 | -465 | -400 | N/A |
| 3/31/2021 | 28 | -337 | -435 | -370 | N/A |
| 12/31/2020 | 28 | -319 | -402 | -344 | N/A |
| 9/30/2020 | 28 | -292 | -318 | -271 | N/A |
| 6/30/2020 | N/A | -249 | -276 | -250 | N/A |
| 3/31/2020 | N/A | -354 | -234 | -215 | N/A |
| 12/31/2019 | N/A | -462 | -196 | -180 | N/A |
| 9/30/2019 | N/A | -747 | -166 | -155 | N/A |
| 12/31/2018 | 1 | -440 | -124 | -112 | N/A |
| 12/31/2017 | N/A | -146 | N/A | -108 | N/A |
| 12/31/2016 | 0 | -128 | N/A | -57 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688266 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.9%).
Earnings vs Market: 688266 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 688266 is expected to become profitable in the next 3 years.
Revenue vs Market: 688266's revenue (55.8% per year) is forecast to grow faster than the CN market (14.1% per year).
High Growth Revenue: 688266's revenue (55.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688266's Return on Equity is forecast to be low in 3 years time (9.9%).